Literature DB >> 3718016

HLA antigens in Italian patients with primary Sjögren's syndrome.

C Vitali, A Tavoni, G Rizzo, R Neri, A D'Ascanio, R Cristofani, S Bombardieri.   

Abstract

Twenty eight Italian patients with primary Sjögren's syndrome were typed for class I and class II alloantigens of the major histocompatibility complex. Patients with Sjögren's syndrome had higher prevalence of DR3 (46.4% v 14% in the control population, p corrected less than 0.02), while similar prevalence was found for DR2 and DRw52 alloantigens. DR3 correlated with DRw52 (p less than 0.0001), anti-Ro(SSA) (p less than 0.0002) and anti-La(SSB) (p less than 0.02) antibodies, and extraglandular manifestations (p less than 0.02). In addition, extraglandular involvement was associated with anti-Ro antibodies (p less than 0.05) and raised gammaglobulins (p less than 0.02). In Italian patients with primary Sjögren's syndrome DR3 is the genetic marker related to this clinical entity and seems to identify a disease subset characterised by autoantibody production and extraglandular manifestations.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3718016      PMCID: PMC1001902          DOI: 10.1136/ard.45.5.412

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  19 in total

1.  Identification of antibodies to nuclear acidic antigens by counterimmunoelectrophoresis.

Authors:  N Kurata; E M Tan
Journal:  Arthritis Rheum       Date:  1976 May-Jun

2.  Systemic lupus erythematosus in the community. Incidence, prevalence, outcome, and first symptoms; the high prevalence in black women.

Authors:  W J Fessel
Journal:  Arch Intern Med       Date:  1974-12

3.  Characterization of a soluble cytoplasmic antigen reactive with sera from patients with systemic lupus erythmatosus.

Authors:  G Clark; M Reichlin; T B Tomasi
Journal:  J Immunol       Date:  1969-01       Impact factor: 5.422

4.  Neonatal lupus erythematosus with heart block: family study of a patient with anti-SS-A and SS-B antibodies.

Authors:  M D Lockshin; A Gibofsky; C L Peebles; I Gigli; M Fotino; S Hurwitz
Journal:  Arthritis Rheum       Date:  1983-02

5.  HLA and diseases in Japanese.

Authors:  K Hoshino; H Inouye; T Unokuchi; M Ito; K Tsuji
Journal:  Tissue Antigens       Date:  1977-07

6.  Age, sex, and race effects on mortality from systemic lupus erythematosus in the United States.

Authors:  R A Kaslow; A T Masi
Journal:  Arthritis Rheum       Date:  1978-05

7.  Relationshipp of HLA-Dw3 and HLA-B8 to Sjögren's syndrome.

Authors:  K H Fye; P I Terasaki; J P Michalski; T E Daniels; G Opelz; N Talal
Journal:  Arthritis Rheum       Date:  1978-04

8.  The distribution of DR5, MT2, and MB3 specificities on human Ia subsets.

Authors:  N Tanigaki; R Tosi; K Sagawa; J Minowada; G B Ferrara
Journal:  Immunogenetics       Date:  1983       Impact factor: 2.846

9.  Lung involvement in Sjögren's syndrome: a comparison between patients with primary and with secondary syndrome.

Authors:  C Vitali; A Tavoni; G Viegi; E Begliomini; A Agnesi; S Bombardieri
Journal:  Ann Rheum Dis       Date:  1985-07       Impact factor: 19.103

10.  Sjögren's syndrome association with HLA-Dw3.

Authors:  T M Chused; S S Kassan; G Opelz; H M Moutsopoulos; P I Terasaki
Journal:  N Engl J Med       Date:  1977-04-21       Impact factor: 91.245

View more
  3 in total

Review 1.  Genetics of Sjögren's syndrome.

Authors:  Leyla Y Teos; Ilias Alevizos
Journal:  Clin Immunol       Date:  2017-05-03       Impact factor: 3.969

Review 2.  Contribution of Genetic Factors to Sjögren's Syndrome and Sjögren's Syndrome Related Lymphomagenesis.

Authors:  Adrianos Nezos; Clio P Mavragani
Journal:  J Immunol Res       Date:  2015-10-15       Impact factor: 4.818

3.  Epitope Mapping of Pathogenic Autoantigens on Sjögren's Syndrome-Susceptible Human Leukocyte Antigens Using In Silico Techniques.

Authors:  Shivai Gupta; Danmeng Li; David A Ostrov; Cuong Q Nguyen
Journal:  J Clin Med       Date:  2022-03-18       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.